Generic drug manufacturer, in DM, CV, CNS, infection, respiratory, GI, ophthalmic, otic and dermatological therapeutic areas.
Has been granted 41 ANDA approvals, of which includes 13 bioequivants (company website, March 2017)
Covers the entire pharmaceutical supply chain from research and development to sales and distribution. Provides outsourced R&D and manufacturing services for domestic and multinational pharmaceutical companies. PIC/S certified.
Virtually operating company, focusing on developing new drugs in various areas including oncology and infectious disease. Focusing on translational medicine stage of drug development, team surveys many small molecules, peptides, biologics, and platform technologies at the lead optimization stage. Projects are brought into BRIM through co-development partnerships or in-licensing deals, and development of the projects is conducted at global CROs and CMOs that fit the needs of the project. Once clinical proof of concept (POC) is reached, the projects are partnered out for further clinical development.
Pharmaceutical and medical device technology development company.
Specialized in controlled-release drug delivery technology research and production of patch products for pharmaceutical and consumer applications.
Pharmaceutical manufacturer, specializing in oral liquid drugs. Certified PIC/S
Primarily generic pharmaceuticals. Strategy is to provide niche and high manufacturing complexity API and generic drugs, as well as 505(b)(2) class new drugs (new route of administration, new derivatives, new use, etc.).
Six manufacturing facilities in Taiwan.
Chunghwa Chemical Synthesis & Biotech Co., Ltd.: API manufacturer
Suzhou Chunghwa Chemical & Pharmaceutical Industrial Co., Ltd. (China)
Suzhou Chunghwa Yuming Pharmaceutical Co., Ltd. (China)
Chunghwa Yuming Healthcare Co., Ltd. (drug distribution)
Chunghwa Senior Care Co., Ltd. (seniors health care services)
Phermpep Co., Ltd. (peptide-based products for health)
Tai Rung Development Co., Ltd. (packaging products, ampoules, etc.)
API manufacture for small and large molecule drugs.
Facilities consist of seven areas for fermentation, purification and chemical synthesis for production ranging from kilograms to multiple tons. Fermentation capacity ranges from 75L to 50,000L. Purification and synthesis ranging from 30L to 8,000L.
Subsidiary of China Chemical & Pharmaceutical Co., Ltd.
1. Rapid development and commercialization of new drugs using its proprietary drug delivery technology. Targeting indications through the 505(b)(2) regulatory pathway. Products under development are FP-001 (prostate cancer), FP-004 (opiate drug addiction), FP-002 (acromegaly), and FP-008 (diabetic retinopathy).
2. Rationally-designed small molecule candidates, designed through medicinal chemistry screening and lead optimization. Products currently under development are FP-025 (asthma / chronic obstructive pulmonary disease) and FP-020 (Alport syndrome).
New drugs in clinical trials are FP-001 LMIS 50mg (prostate cancer), currently in a multinational multi-center phase III registration study in the US, Europe and Taiwan, and FP-025 (a small molecule MMP-12 inhibitor for the treatment of asthma / chronic obstructive pulmonary disease), in a First-in-Human Phase I study in Taiwan.
Foresee Pharmaceuticals also has a US office.